Full metadata record
DC FieldValueLanguage
dc.creatorDelforge, M. (M.)-
dc.creatorRodriguez-Otero, P. (Paula)-
dc.creatorShah, N. (Nina)-
dc.creatorMoshkovich, O. (Olga)-
dc.creatorBraverman, J. (Julia)-
dc.creatorDhanda, D.S. (Devender S.)-
dc.creatorLanar, S. (Sally)-
dc.creatorDevlen, J. (Jennifer)-
dc.creatorMiera, M. (Matthew)-
dc.creatorGerould, H. (Heather)-
dc.creatorCampbell, T.B. (Timothy B.)-
dc.creatorMunshi, N.C. (Nikhil C.)-
dc.date.accessioned2023-06-07T10:37:02Z-
dc.date.available2023-06-07T10:37:02Z-
dc.date.issued2023-
dc.identifier.citationDelforge, M.; Rodríguez-Otero, P. (Paula); Shah, N.; et al. "Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial". Leukemia Research. 129, 2023, 107074es
dc.identifier.issn0145-2126-
dc.identifier.urihttps://hdl.handle.net/10171/66567-
dc.description.abstractObjective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial.Methods: This qualitative study analyzed semi-structured patient interviews 6-24 months after ide-cel infusion. Thematic analysis with quantitative and longitudinal analyses explored patient perceptions of ide-cel treatment experience, advantages and disadvantages, and long-term health-related quality of life impact. Patient journeys were developed from narrative analysis of perceived treatment benefits with known remission length.Results: Interviews with 45 patients 6-24 months postinfusion were analyzed; all reported >= 1 ide-cel treatment advantage, most often related to efficacy (n = 42/45, 93%), few or no side effects (n = 35/45, 78%), and avoidance of other treatments (n = 34/45, 76%). Patients generally reported 6-month improvements in physical health, functioning, emotional well-being, social life, and outlook on the future; these improvements mostly remained stable through 18 and 24 months. The most common patient journeys comprised physical, func-tioning, or emotional benefit with remission < 2 years.Conclusions: Longitudinal analysis of patient experiences showed sustained benefits and preference for ide-cel up to 24 months after treatment.Trial Registration Number and Date: NCT03361748. December 5, 2017.-
dc.description.sponsorshipThis study was funded by Celgene, a Bristol-Myers Squibb Company, in collaboration with 2seventy bio-
dc.language.isoen-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.subjectCAR T cell therapy-
dc.subjectIdecabtagene vicleucel-
dc.subjectPatient experience-
dc.subjectPatient-reported outcomes-
dc.subjectRelapsed or refractory multiple myeloma-
dc.subjectTriple-class exposed-
dc.titleAnalysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial-
dc.typeinfo:eu-repo/semantics/article-
dc.relation.publisherversionhttps://pubmed.ncbi.nlm.nih.gov/37087950/-
dc.description.noteThis is an open access article under the CC BY-NC-ND license-
dc.identifier.doi10.1016/j.leukres.2023.107074-
dadun.citation.publicationNameLeukemia Research-
dadun.citation.startingPage107074-
dadun.citation.volume129-
dc.identifier.pmid37087950-

Files in This Item:
Thumbnail
File
pdf.pdf
Description
Size
3.65 MB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.